• NEWS
  • NEWS
  • NEWS
  • NEWS
  • NEWS
  • NEWS

The latest news on XGEN and its companies.

Linkedin

Follow us on LinkedIn

  • Press Release - XGEN News

XGEN Venture Announces €160 million First Life Science Fund

  • Business Wire
XGEN Venture – a newly formed Venture Capital firm - announces its first fund, XGEN Venture Life Science Fund, with...
  • Portfolio Company News - Press Release

Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial

  • PROTEMBIS
Protembis GmbH (Protembis) a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the...
  • Portfolio Company News - Press Release

Protembis Announces Completion of € 30 Million Series B Financing Round and the Addition of Keith D Dawkins MD to the Board of Directors

  • Protembis
Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the completion of a € 30 million Series...
  • Portfolio Company News - Press Release

Swiss cancer vaccine biotech Nouscom raises $72M Series C for PhII trials

  • Nouscom
Basel-based biotech Nouscom has raised €67.5 million ($72.2 million) to bankroll its cancer vaccines as the eight-year-old company looks to...
xgen logo white
Quick Links
Get In Touch
Via Privata Giovannino De Grassi, 11
20123 Milan
XGEN Venture SGR SpA
Board of Directors

Prof. Carlo Marchetti – Independent Chairman
Carlo Michero – Independent Member
Paolo Fundarò – Chief Executive Officer
Federica Draghi – Member
Daniele Scarinci – Member

Copyright © 2023 XGEN Venture SGR S.p.A | Sede legale: Via Privata Giovannino de Grassi 11, 20123 Milano. Capitale sociale Euro 50.000,00. Numero di iscrizione al Registro Imprese di Milano Monza Lodi Brianza, Codice Fiscale e Partita IVA: 11840730961. Numero iscrizione Albo dei Gestori FIA 200.